Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell lines

International Journal of Cancer

Volumn 55, Issue 4, 1993, Pages 678-684

  Brown, Robert ^a,b   Clugston, Carol ^a   Edlin, Angela ^a   Vasey, Paul ^a   Kaye, Stanley B ^a   Burns, Philip ^a,c   Vojtěšek, Borek ^a,d  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

CELL CYCLE; CISPLATIN; DNA DAMAGE; DRUG RESISTANCE; FEMALE; HUMAN; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEIN P53; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0027369120     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910550428     Document Type: Article

References (29)

1. Cellular pharmacology of CDDP: perspectives on mechanisms of acquired resistance
2. Suppression of human colorectal carcinoma cell growth by wild‐type p53
3. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines
4. Characterisation of a cis‐diamminedichloroplatinum resistant human ovarian cell line and its use in evaluation of platinum analogues
5. Modulation of activity of the promoter of the human mdr 1 gene by Ras and p53
6. Thymocyte apoptosis induced by p53‐dependent and independent pathways
7. Multidrug resistance in cells transfected with human genes encoding a variant P‐glycoprotein and glutathione S‐transferase pi
8. Wild‐type p53 activates transcription in vitro
9. Induction of nuclear accumulation of the tumour‐suppressor protein p53 by DNA‐damaging agents
10. Activating mutations in p53 produce a common conformational effect. A monoclonal specific for the mutant form
11. Wild‐type p53 adopts a “mutant”‐like conformation when bound to DNA
12. Hypervariable minisatellite regions in human DNA
13. Participation of p53 protein in the cellular response to DNA damage
14. Establishment and characterisation of an in vitro model of acquired resistance to cisplatin in a human testicular non‐seminomatous germ cell line
15. Mechanism‐related circumvention of acquired cis‐diamminedichloroplatinum (II) resistance using two pairs of human ovarian carcinoma cell lines by amine/amine platinum IV dicarboxylates
16. Wild‐type p53 is a cell‐cycle checkpoint determinant following irradiation
17. p53 mutations increase resistance to ionising radiation
18. Altered cell cycle arrest and gene amplification potential accompany loss of wild‐type p53
19. Radiation survival parameters of antineoplastic drug‐sensitive and resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine
20. Ras‐induced hyperplasia occurs with mutations of p53, but activated ras and myc together can induce carcinoma without p53 mutations
21. Single‐step selection of cisplatin resistant mutants from a human ovarian cell line
22. Construction of activated mutant p53 with wild‐type drives the wild‐type p53 protein into the mutant conformation
23. Constitutive expression of p53 protein in enriched normal human marrow blast cell population
24. p53 mutations in colorectal cancer
25. Drug related chromosomal changes in chemoresistant human ovarian carcinoma cells
26. p53 function and disfunction
27. An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53
28. p53‐mediated cell death: relationship to cell cycle control
29. Increased gene‐specific repair of cisplatin interstrand cross‐links in cisplatin‐resistant human ovarian cancer cell lines